COVID-19

The leadership team of ARVO give us an insight into how the organization has grown in challenging times

How has glaucoma care and management changed since the start of 2020?

PolyPhotonix names Prevail Partners as its lead US investor whose affiliate will lead Noctura 400 FDA clinical trials

On the second anniversary of Li Wenliang's death, we remember the brave novel coronavirus whistleblower

During a live roundtable, esteemed ocular surface experts discussed steps practices can take to effectively manage patients’ dry eye disease

Improving artificial intelligence development using blockchain – where digital health technologies converge

Philip Rosenfeld, an inspiration to the world of retina, shares his life story and his views in an interview with Omer Trivizki

Gerd U. Auffarth talks about his experiences with the ESCRS Congress, milestones in the cataract and refractive field, and life during the pandemic

Noctura 400 from PolyPhotonix offers a revolutionary, home-based non-invasive diabetic retinopathy treatment that reduces oxygen demand in the retina

Sitting Down With… Mariya Moosajee, Professor of Molecular Ophthalmology at University College London Institute of Ophthalmology